BCRX: BioCryst Pharmaceuticals, Inc. Price to Sales
BioCryst has developed a precise targeted drug delivery system, ensuring the safety of therapies for rare pathologies. The company's P/S ratio effectively filters out market noise, demonstrating a transparent business valuation trend, where the current mark is 2.00. Global sales reach across Japan, Europe, and the US mitigates country-specific risks, while a steady cash flow fully covers capital expenditures and liabilities.
Analytical breakdowns for BioCryst Pharmaceuticals Inc (BCRX)
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
- financial results and valuation multiples details:
BCRX - Net Income|Future Net Profit BioCryst|BCRX - P/E Multiple|Future Price to Earnings BioCryst Pharmaceuticals, Inc.|BCRX - PEG Multiple|Enterprise Value to EBITDA Ratio BioCryst Pharmaceuticals Inc|BCRX - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year BioCryst|BCRX - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last 12 months biocryst.com|BCRX - Earnings per share growth in current year|Net earnings per share change forecast for next year BioCryst
- issuer revenue and sales details:
Fundamental company analysis:biocryst.com, BCRX
The high scalability of BioCryst (BCRX) oral medications reduces production costs, which directly impacts revenue dynamics and the market value of assets. The P/S ratio compares market capitalization to sales volume, determining the premium the market is willing to pay per unit of revenue; by analyzing the price-to-sales trend, an investor can timely recognize valuation overheating and avoid the risks of a deep correction.
Who BioCryst competes with
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA Bio - P/S Multiple|PTGX: Price-to-Revenue Ratio|IMVT: P/S Multiple|KNSA - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Grifols|Price to Sales Adaptive Biotech ADPT|P/S Multiple CLDX|Market Cap to Revenue Aurinia Corp AUPH|Price-to-Revenue Ratio Vera Therapeutics, Inc. VERA|Market Capitalization-to-Revenue Ratio DNTH|PHVS: Market Cap to Revenue|Price to Sales AbCellera Biologics Inc.|Tourmaline Corp (TRML) - Price-to-Revenue Ratio|PGEN - Price-to-Revenue Coefficient|Market Cap to Revenue PHAR|NKTR (nektar.com) - Market Cap to Sales Volume|P/S Multiple UPB|Price-to-Revenue Ratio ZBIO (Zenas Bio)|P/S Multiple IMNM (Immunome Corp)|GOSS - Market Cap to Revenue|KALV - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio SEPN (septerna.com)|PVLA (Pieris Pharmaceuticals, Inc.) - Market Cap to Revenue|Market Cap to Revenue Ratio SVRA|Price-to-Revenue Ratio Rigel Pharmaceuticals Inc|AnaptysBio Inc. - Price-to-Sales Ratio|P/S Multiple ATXS|ENGN (engene.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple RAPT (RAPT Therapeutics)|P/S Multiple Aerovate Therapeutics, Inc. JBIO|ACRS - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio KYTX (Kyverna Therapeutics, Inc)|Tiziana Life Sciences (TLSA) - Price-to-Revenue Ratio|Market Cap to Revenue cabalettabio.com|VTYX (Ventyx Biosciences, Inc.) - P/S Multiple|P/S Multiple Theratechnologies, Inc.|Market Cap to Revenue AVTX (Avalo Therapeutics Inc.)|ELDN (Eledon Pharmaceuticals, Inc) - Market Capitalization-to-Revenue Ratio|P/S Multiple AGEN (Agenus)|Price-to-Revenue Coefficient climbbio.com (CLYM)|ZURA - Price-to-Revenue Ratio|aTyr Pharma Inc (ATYR) - Market Cap to Revenue|adagene.com (ADAG) - Price-to-Revenue Ratio|Market Cap to Revenue Ikena Oncology|Market Cap to Revenue STTK|P/S Multiple Equillium Bio|Price-to-Revenue Ratio Connect Biopharma (CNTB)|immunic-therapeutics.com - Market Cap to Revenue Ratio|P/S Multiple ATRA (Atara Bio)|InflaRx NV (IFRX) - Price to Sales|X4 Pharmaceuticals - P/S Multiple|ACET: Price-to-Revenue Ratio|CELU: P/S Multiple|INMB - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Barinthus Bio|Price to Sales Kezar Life Sciences Inc KZR|P/S Multiple SABS|Market Cap to Revenue akaritx.com AKTX|Price-to-Revenue Ratio Enlivex Therapeutics Ltd. ENLV|Market Capitalization-to-Revenue Ratio QTTB|GOVX: Market Cap to Revenue|Price to Sales Edesa Biotech Corp|iBio, Inc. (IBIO) - Price-to-Revenue Ratio|CARM - Price-to-Revenue Coefficient|Market Cap to Revenue XTLB|BOLT (Bolt Bio) - Market Cap to Sales Volume|P/S Multiple HCWB|Price-to-Revenue Ratio APVO (aptevotherapeutics.com)|P/S Multiple AIM (AIM ImmunoTech Inc.)|ADTX - Market Cap to Revenue|GRI - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio XRTX (XORTX Therapeutics Inc)|HIND (ReShape Lifesciences) - Market Cap to Revenue|Market Cap to Revenue Ratio REVB|Price-to-Revenue Ratio Indaptus Therapeutics|scinai.com - Price-to-Sales Ratio|P/S Multiple CALI|AFMD (affimed.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple ALLK (Allakos)|P/S Multiple HOOKIPA Pharma, Inc. HOOK|IGMS - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio ITOS (iteostherapeutics.com)|Ocean Biomedical (OCEA) - Price-to-Revenue Ratio|Market Cap to Revenue TC BioPharm (Holdings) Plc|THRD (Third Harmonic Bio, Inc) - P/S Multiple
